InvestorsHub Logo
Followers 6
Posts 756
Boards Moderated 0
Alias Born 01/10/2022

Re: Tiger Money post# 730

Wednesday, 02/02/2022 11:35:51 AM

Wednesday, February 02, 2022 11:35:51 AM

Post# of 1226
The timing everyone is hinting at is the finalization of the merger between GASE and Curadox. Below is some DD from user Harv on twitter;

"Big bio-opportunity: Sean, CEO of $GASE, Perasky is with Curadox.
Last time Sean and Perasky did a merger .40 to $3
This time, 8 million float"

"Curadox Biopharma, Inc. (CBI) will develop its
first product, CB-TD1, as a minimally toxic
treatment for ovarian cancer. CB-TD-1 has
already shown compelling results in in vitro
testing performed by the National Cancer Institute"

The incoming CFO is James Pekarsky. He is the former CEO of NYSE American-listed BioPharmX. SCM Capital helped do an offering and last year BioPharmX merged with the private company Timber Pharmaceuticals with 20 million in funding"